Zometa and Pentacarinat drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zometa (zoledronic acid) and Pentacarinat (pentamidine isethionate). Common drug interactions include neutropenia among females and loss of consciousness among males.

The phase IV clinical study analyzes what interactions people have when they take Zometa and Pentacarinat. It is created by eHealthMe based on reports of 41 people who take the same drugs from the FDA, and is updated regularly.

What is Zometa?

Zometa has active ingredients of zoledronic acid. It is often used in multiple myeloma. eHealthMe is studying from 71,434 Zometa users. Check the latest studies of Zometa.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.

On Jul, 08, 2026

41 people who take Zometa and Pentacarinat together, and have interactions are studied.

Zometa and Pentacarinat drug interactions.

What are the common drug interactions of Zometa and Pentacarinat, by gender? *:

female:

Neutropenia (an abnormally low number of neutrophils)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Anaemia (lack of blood)
Pulmonary embolism (blockage of the main artery of the lung)
Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot)
Asthenia (weakness)
Back pain
Gingivitis (inflammation of gums)
Infusion related reaction
Rotator cuff syndrome (a spectrum of conditions affecting the rotator cuff tendons of the shoulder)

male:

Loss of consciousness
Diarrhoea
Diverticular perforation (serious gastrointestinal condition in which the intestine's walls are perforated)
Gastrointestinal perforation (hole in the digestive tract)
Confusional state
Delusion (a false belief or opinion)
Dental caries
Exposed bone in jaw
General physical health deterioration (weak health status)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

What are the common drug interactions of Zometa and Pentacarinat, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Dental caries
Exposed bone in jaw
Osteonecrosis of jaw (death of bone of jaw)
Pain in jaw

60+:

Neutropenia (an abnormally low number of neutrophils)
Loss of consciousness
Anaemia (lack of blood)
Colitis (inflammation of colon)
Pulmonary embolism (blockage of the main artery of the lung)
Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot)
Asthenia (weakness)
Back pain
Diverticular perforation (serious gastrointestinal condition in which the intestine's walls are perforated)
Gastrointestinal perforation (hole in the digestive tract)

What are the existing conditions these people have? *

High Blood Pressure: 13 people, 31.71%
Constipation: 9 people, 21.95%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 8 people, 19.51%
Hyperglycemia (high blood sugar): 8 people, 19.51%
Lymphoma (cancer that begins in immune system cells): 6 people, 14.63%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 6 people, 14.63%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 6 people, 14.63%
Insomnia (sleeplessness): 6 people, 14.63%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 6 people, 14.63%
Osteoporosis (bones weak and more likely to break): 6 people, 14.63%

* Approximation only. Some reports may have incomplete information.

Do you take Zometa and Pentacarinat?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously